ACHV Achieve Life Sciences Inc.

2.42
0  0%
Previous Close 2.42
Open
Price To Book 1.86
Market Cap 18,937,870
Shares 7,825,566
Volume 214
Short Ratio
Av. Daily Volume 261,798

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data met primary endpoint in 3/4 arms - June 11, 2019.
Cytisine
Smoking cessation

Latest News

  1. ACHV: ORCA-1 Topline Results and Comparison
  2. Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial
  3. Achieve Receives $4.2 Million from Exercise of Warrants
  4. ACHV: 1Q:19 Financial & Operational Update
  5. Achieve Announces Patent Granted in the U.S. for Novel Formulation of Cytisinicline
  6. Achieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update
  7. Achieve Life Sciences to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 15, 2019
  8. ACHV: Final Enrollee, Final Visit
  9. Achieve Life Sciences Announces Last Subject, Last Visit Completed in Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation
  10. Achieve Life Sciences to Present at HC Wainwright Global Life Sciences Conference on April 8, 2019
  11. The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial
  12. Achieve Life Sciences Announces Successful Completion of the Second and Final DSMC Review of Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation
  13. ACHV: Fiscal Year 2018 Operational and Financial Results
  14. What Do the Clinical Updates at Achieve Life Sciences Mean for Cytisinicline
  15. Achieve Life Sciences to Present at Oppenheimer's 29th Annual Healthcare Conference on March 20, 2019
  16. Four Healthcare Stocks Picking Up Speed On Friday